-
1
-
-
0029050331
-
Intravesical mitozantrone in recurrent superficial bladder cancer: A phase II study
-
Namasivayam S, Whelan P: Intravesical mitozantrone in recurrent • superficial bladder cancer: a phase II study. Br J Urol 1995, 75:740-743. The first description of phase II results with a new active intravesical agent.
-
(1995)
Br J Urol
, vol.75
, pp. 740-743
-
-
Namasivayam, S.1
Whelan, P.2
-
2
-
-
0029153752
-
Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction
-
Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, •• Groshen S, Lieskovsky G, Boyd SD, Skinner DG: Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1996, 76:833-839. A good assessment of the prognostic factors, which may dictate the need for early radical surgery.
-
(1996)
Cancer
, vol.76
, pp. 833-839
-
-
Freeman, J.A.1
Esrig, D.2
Stein, J.P.3
Simoneau, A.R.4
Skinner, E.C.5
Chen, S.C.6
Groshen, S.7
Lieskovsky, G.8
Boyd, S.D.9
Skinner, D.G.10
-
3
-
-
0028946881
-
Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transition cell carcinoma of the bladder
-
Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of •• current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transition cell carcinoma of the bladder. J Urol 1995, 53:1444-1450. This retrospective analysis of many studies of intravesical chemotherapy shows that, currently, no agent has influenced the rate of progression in superficial bladder cancer.
-
(1995)
J Urol
, vol.53
, pp. 1444-1450
-
-
Lamm, D.L.1
Riggs, D.R.2
Traynelis, C.L.3
Nseyo, U.O.4
-
4
-
-
0028900687
-
Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial
-
Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S, and the BLP •• Study Group: Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol 1995, 27:104-109. First prospective randomized study of Lactobacillus casei showing a significant effect of this agent.
-
(1995)
Eur Urol
, vol.27
, pp. 104-109
-
-
Aso, Y.1
Akaza, H.2
Kotake, T.3
Tsukamoto, T.4
Imai, K.5
Naito, S.6
-
5
-
-
0026531056
-
Phase I trial of oral bropirimine in superficial bladder cancer
-
Sarovsky MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA: Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 1992, 147:31-33.
-
(1992)
J Urol
, vol.147
, pp. 31-33
-
-
Sarovsky, M.F.1
Lamm, D.L.2
Williams, R.D.3
Moon, T.D.4
Flanigan, R.C.5
Crawford, E.D.6
Wilks, N.E.7
Earhart, R.H.8
Merritt, J.A.9
-
6
-
-
0029315694
-
Chemotherapy and immunotherapy: How do we assess their effectiveness and what are their limitations and uses?
-
Lamm DL, Van der Meijden APM, Akaza H: Chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995, 2(suppl 2):23-33.
-
(1995)
Int J Urol
, vol.2
, Issue.2 SUPPL.
, pp. 23-33
-
-
Lamm, D.L.1
Van Der Meijden, A.P.M.2
Akaza, H.3
-
7
-
-
0000420318
-
Current status of intravesical therapy for bladder cancer
-
Edited by Ruysch S. New York, WW North & Co.;
-
Traynelis CL, Lamm DL: Current status of intravesical therapy for bladder cancer. In Urology Annual. Edited by Ruysch S. New York, WW North & Co.; 1994:113-143.
-
(1994)
Urology Annual
, pp. 113-143
-
-
Traynelis, C.L.1
Lamm, D.L.2
-
8
-
-
0004643513
-
Adjuvant therapy of superficial transitional cell carcinoma - An EORTC randomized trial comparing doxorubicin, ethoglucid and TUR alone
-
Edited by Schröder FH, Ricards B. New York: Alan R. Liss
-
Kurth KH, Schröder FH, Senge T, De Bruyne FMJ, Carpentier PJ, Riedl H, Sylvester R, de Paul M and members of the EORTC GU-Group: Adjuvant therapy of superficial transitional cell carcinoma - an EORTC randomized trial comparing doxorubicin, ethoglucid and TUR alone. In Superficial Bladder Tumours. Edited by Schröder FH, Ricards B. New York: Alan R. Liss, 1985: 135-142.
-
(1985)
Superficial Bladder Tumours
, pp. 135-142
-
-
Kurth, K.H.1
Schröder, F.H.2
Senge, T.3
De Bruyne, F.M.J.4
Carpentier, P.J.5
Riedl, H.6
Sylvester, R.7
De Paul, M.8
-
9
-
-
0028946881
-
Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder
-
Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder. J Urol 1995, 153:1444-1450.
-
(1995)
J Urol
, vol.153
, pp. 1444-1450
-
-
Lamm, D.L.1
Riggs, D.R.2
Traynelis, C.L.3
Nseyo, U.O.4
-
10
-
-
0027506241
-
An EORTC GU-Group randomized trial comparing TUR followed by a single instillation of epirublcln or water in single stage Ta T1 carcinoma of the bladder
-
Oosterlinck W, Kurth KH, Schröder FH, Bultinck J, Hammond B, Sylvester R, and members of the EORTC GU-Group. An EORTC GU-Group randomized trial comparing TUR followed by a single instillation of epirublcln or water in single stage Ta T1 carcinoma of the bladder. J Urol 1993, 149:749-752.
-
(1993)
J Urol
, vol.149
, pp. 749-752
-
-
Oosterlinck, W.1
Kurth, K.H.2
Schröder, F.H.3
Bultinck, J.4
Hammond, B.5
Sylvester, R.6
-
11
-
-
0023629845
-
Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer
-
The Japanese Urological Cancer Research Group for Adriamycin.
-
Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Maru A, Matsumura Y, Niijima T, Obata K, Ohe H, et al.: The Japanese Urological Cancer Research Group for Adriamycin. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemother Pharmacol 1987, Suppl 20:91-96.
-
(1987)
Cancer Chemother Pharmacol
, vol.20 SUPPL
, pp. 91-96
-
-
Akaza, H.1
Isaka, S.2
Koiso, K.3
Kotake, T.4
Machida, T.5
Maru, A.6
Matsumura, Y.7
Niijima, T.8
Obata, K.9
Ohe, H.10
-
12
-
-
0028909214
-
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 EORTC randomized trials with Mitomycin C and Doxorubicin comparing early versus delayed instillations and short term versus long term treatment
-
Bouffioux, Kurth KH, Bono A, Oosterlinck C, Boeken Kruger W, de Paul M, Sylvester R, and the members of the EORTC GU-Group: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 EORTC randomized trials with Mitomycin C and Doxorubicin comparing early versus delayed instillations and short term versus long term treatment J Urol 1995, 153:934-941.
-
(1995)
J Urol
, vol.153
, pp. 934-941
-
-
Bouffioux1
Kurth, K.H.2
Bono, A.3
Oosterlinck, C.4
Boeken Kruger, W.5
De Paul, M.6
Sylvester, R.7
-
13
-
-
10244256788
-
Intracavitary BCG in the treatment of superficial bladder tumours
-
Morales A, Eidinger, Bruce AW: Intracavitary BCG in the treatment of superficial bladder tumours. J Urol 1976, 116:18-23.
-
(1976)
J Urol
, vol.116
, pp. 18-23
-
-
Morales, A.1
Eidinger2
Bruce, A.W.3
-
14
-
-
0028962090
-
BCG in perspective: Advances in the treatment of superficial bladder cancer
-
Lamm DL. BCG in perspective: advances in the treatment of •• superficial bladder cancer. Eur Urol 1995, 27(suppl 1):2-8. A useful update of a knowledge of BCG therapy, including the question of maintenance dosing.
-
(1995)
Eur Urol
, vol.27
, Issue.1 SUPPL.
, pp. 2-8
-
-
Lamm, D.L.1
-
15
-
-
0028953614
-
BCG enhances monocyte and lymphocyte controlled bladder tumour cell killing
-
Prior K, Goddard J, Goldstein D, Strikker P, Russel P, Golovsky D, Penny R: BCG enhances monocyte and lymphocyte controlled bladder tumour cell killing. Br J Cancer 1995, 71:801-807.
-
(1995)
Br J Cancer
, vol.71
, pp. 801-807
-
-
Prior, K.1
Goddard, J.2
Goldstein, D.3
Strikker, P.4
Russel, P.5
Golovsky, D.6
Penny, R.7
-
16
-
-
0028909213
-
A randomized study of intravesical MMC, BCG Tice and BCG RIVM treatment in Ta, T1 papillary carcinoma and carcinoma in situ of the bladder
-
Vegt PDJ, Witjes A, Witjes WPT, Witjes JE, Witjes WPJ, Doesburg WH, DeBruyne FMJ, Van der Meyden EPM: A randomized study of intravesical MMC, BCG Tice and BCG RIVM treatment in Ta, T1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995, 153:929-933.
-
(1995)
J Urol
, vol.153
, pp. 929-933
-
-
Vegt, P.D.J.1
Witjes, A.2
Witjes, W.P.T.3
Witjes, J.E.4
Witjes, W.P.J.5
Doesburg, W.H.6
DeBruyne, F.M.J.7
Van Der Meyden, E.P.M.8
-
17
-
-
0028967945
-
Practical approaches to the prevention and treatment of adverse reactions to BCG
-
Van der Meijden APM: Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur Urol 1995, 27(suppl 1):23-28.
-
(1995)
Eur Urol
, vol.27
, Issue.1 SUPPL.
, pp. 23-28
-
-
Van Der Meijden, A.P.M.1
-
18
-
-
0028948874
-
Low dose BCG therapy in superficial high risk bladder cancer: A phase II study with BCG strain Connaught Canada
-
Mack D, Fnck J: Low dose BCG therapy in superficial high risk bladder cancer: a phase II study with BCG strain Connaught Canada. Br J Urol 1995, 75:185-187.
-
(1995)
Br J Urol
, vol.75
, pp. 185-187
-
-
Mack, D.1
Fnck, J.2
-
19
-
-
0028962091
-
Improving the efficacy of BCG immunotherapy by dose reduction
-
Pagano F, Bassi P, Piazza N, Abatangelo G, Drago Ferrante GL, Milani C: Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995, 27(suppl 1):19-22.
-
(1995)
Eur Urol
, vol.27
, Issue.1 SUPPL.
, pp. 19-22
-
-
Pagano, F.1
Bassi, P.2
Piazza, N.3
Abatangelo, G.4
Drago Ferrante, G.L.5
Milani, C.6
-
20
-
-
0029053868
-
Intravesical BCG therapy prevents tumour progression and death from superficial bladder cancer: Ten year follow-up of a prospective randomized trial
-
Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore jr. •• WF, Oettgen HF: Intravesical BCG therapy prevents tumour progression and death from superficial bladder cancer: ten year follow-up of a prospective randomized trial. J Clin Oncol 1995, 13:1404-1408. An important study showing quite clearly that BCG influences the rate of progression in superficial bladder cancer.
-
(1995)
J Clin Oncol
, vol.13
, pp. 1404-1408
-
-
Herr, H.W.1
Schwalb, D.M.2
Zhang, Z.F.3
Sogani, P.C.4
Fair, W.R.5
Whitmore Jr., W.F.6
Oettgen, H.F.7
-
21
-
-
10244266781
-
Intravesical prophylaxis with BCG versus interferon α for superficial bladder cancer
-
Kalbe T, Boer M, Staehler G: Intravesical prophylaxis with BCG versus interferon α for superficial bladder cancer [Abstract]. J Urol 1994, 151:233.
-
(1994)
J Urol
, vol.151
, pp. 233
-
-
Kalbe, T.1
Boer, M.2
Staehler, G.3
-
22
-
-
0023934840
-
Immunotherapy in bladder with KLH - A randomized study
-
Jarinciu CD, Engelmann U, Gasch J, Klippel KF: Immunotherapy in bladder with KLH - a randomized study. J Urol 1988, 139:723-726.
-
(1988)
J Urol
, vol.139
, pp. 723-726
-
-
Jarinciu, C.D.1
Engelmann, U.2
Gasch, J.3
Klippel, K.F.4
-
23
-
-
0028947819
-
Trypthophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective randomized phase III study performed by the EORTC GU-Group
-
Newling DWW, Robinson MRG, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R, and members of the EORTC GU-Group: Trypthophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective randomized phase III study performed by the EORTC GU-Group. Eur Urol 1995, 27:110-116.
-
(1995)
Eur Urol
, vol.27
, pp. 110-116
-
-
Newling, D.W.W.1
Robinson, M.R.G.2
Smith, P.H.3
Byar, D.4
Lockwood, R.5
Stevens, I.6
De Pauw, M.7
Sylvester, R.8
-
24
-
-
0017657105
-
Comparison of pyridoxine, placebo and topical thlotepa in presenting recurrence of stage I bladder carcinoma
-
Byar D, Blackhard C: Comparison of pyridoxine, placebo and topical thlotepa in presenting recurrence of stage I bladder carcinoma. Urology 1977, 10:556-560.
-
(1977)
Urology
, vol.10
, pp. 556-560
-
-
Byar, D.1
Blackhard, C.2
-
25
-
-
0029665257
-
Marker tumour response to the sequential combination of intravesical therapy with MMC and BCG-RIVM in multiple superficial bladder tumours
-
Van der Meijden APM, Hall RR, Pavone Maculuso M, Pawinsky A, Sylvester R, Van Glabbeke M: Marker tumour response to the sequential combination of intravesical therapy with MMC and BCG-RIVM in multiple superficial bladder tumours. Eur Urol 1996, 29:199-203.
-
(1996)
Eur Urol
, vol.29
, pp. 199-203
-
-
Van Der Meijden, A.P.M.1
Hall, R.R.2
Pavone Maculuso, M.3
Pawinsky, A.4
Sylvester, R.5
Van Glabbeke, M.6
|